Follow
Jennifer Bordeaux
Jennifer Bordeaux
Yale University
Verified email at genoptix.com
Title
Cited by
Cited by
Year
Antibody validation
J Bordeaux, AW Welsh, S Agarwal, E Killiam, MT Baquero, JA Hanna, ...
Biotechniques 48 (3), 197-209, 2010
7542010
Antibody validation
J Bordeaux, AW Welsh, S Agarwal, E Killiam, MT Baquero, JA Hanna, ...
Biotechniques 48 (3), 197-209, 2010
7542010
In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis
V Neumeister, S Agarwal, J Bordeaux, RL Camp, DL Rimm
The American journal of pathology 176 (5), 2131-2138, 2010
1752010
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement
DB Johnson, MJ Nixon, Y Wang, DY Wang, E Castellanos, MV Estrada, ...
JCI insight 3 (24), 2018
1382018
Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO-1 predicts improved outcomes of anti–PD-1 therapies in metastatic melanoma
DB Johnson, J Bordeaux, JY Kim, C Vaupel, DL Rimm, TH Ho, ...
Clinical Cancer Research 24 (21), 5250-5260, 2018
1382018
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
H Bitter, JM Bordeaux, B Brannetti, J Brogdon, NK Dakappagari, S Gill, ...
US Patent 10,253,086, 2019
1152019
Lin28 regulates HER2 and promotes malignancy through multiple mechanisms
C Feng, V Neumeister, W Ma, J Xu, L Lu, J Bordeaux, NJ Maihle, ...
Cell cycle 11 (13), 2486-2494, 2012
892012
Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling
PJ Siska, RAN Johnpulle, A Zhou, J Bordeaux, JY Kim, B Dabbas, ...
Oncoimmunology 6 (4), e1305535, 2017
732017
Quantitative in situ measurement of estrogen receptor mRNA predicts response to tamoxifen
JM Bordeaux, H Cheng, AW Welsh, BG Haffty, DR Lannin, X Wu, N Su, ...
PloS one 7 (5), e36559, 2012
642012
Improved prognosis and increased tumor-infiltrating lymphocytes in patients who have SCLC with neurologic paraneoplastic syndromes
WT Iams, E Shiuan, CB Meador, M Roth, J Bordeaux, C Vaupel, KL Boyd, ...
Journal of Thoracic Oncology 14 (11), 1970-1981, 2019
602019
Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma
KE Beckermann, PC Jolly, JY Kim, J Bordeaux, I Puzanov, WK Rathmell, ...
Journal for immunotherapy of cancer 5, 1-5, 2017
442017
Influence of tumor microenvironment on prognosis in colorectal cancer: tissue architecture-dependent signature of endosialin (TEM-1) and associated proteins
DJ O'Shannessy, EB Somers, LK Chandrasekaran, NC Nicolaides, ...
Oncotarget 5 (12), 3983, 2014
392014
Multiplexed ion beam imaging analysis for quantitation of protein expresssion in cancer tissue sections
S Rost, J Giltnane, JM Bordeaux, C Hitzman, H Koeppen, SD Liu
Laboratory investigation 97 (8), 992-1003, 2017
37*2017
CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
H Bitter, JM Bordeaux, B Brannetti, J Brogdon, NK Dakappagari, S Gill, ...
US Patent 11,149,076, 2021
322021
The function, proteolytic processing, and histopathology of Met in cancer
JA Hanna, J Bordeaux, DL Rimm, S Agarwal
Advances in cancer research 103, 1-23, 2009
312009
In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients
M Vassilakopoulou, T Togun, U Dafni, H Cheng, J Bordeaux, ...
PLoS One 9 (6), e99131, 2014
292014
MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC
DA Franklin, JT Sharick, PI Ericsson-Gonzalez, V Sanchez, PT Dean, ...
JCI insight 5 (15), 2020
272020
Neoadjuvant pembrolizumab and high-dose IFNα-2b in resectable regionally advanced melanoma
YG Najjar, D McCurry, H Lin, Y Lin, Y Zang, D Davar, A Karunamurthy, ...
Clinical Cancer Research 27 (15), 4195-4204, 2021
222021
Comparison of HER2 and phospho-HER2 expression between biopsy and resected breast cancer specimens using a quantitative assessment method
Y Bai, H Cheng, J Bordeaux, V Neumeister, S Kumar, DL Rimm, DF Stern
PLoS one 8 (11), e79901, 2013
172013
Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)-expressing cell
H Bitter, JM Bordeaux, B Brannetti, J Brogdon, NK Dakappagari, S Gill, ...
US Patent App. 17/464,528, 2022
122022
The system can't perform the operation now. Try again later.
Articles 1–20